Dimerix Limited ( (AU:DXB) ) has issued an update.
Dimerix Limited has announced the quotation of 23,278 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB, effective March 14, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing development projects, potentially strengthening its position in the biotechnology sector and offering new opportunities for stakeholders.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on the development of innovative therapies for unmet medical needs. The company is primarily engaged in creating treatments for kidney disease and other inflammatory conditions, aiming to address significant gaps in the current healthcare market.
YTD Price Performance: 17.65%
Average Trading Volume: 2,455,686
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$220.7M
See more insights into DXB stock on TipRanks’ Stock Analysis page.